PDC line Pharma
Dissolution or liquidationFinancials · financial year 2024, full format
2024 annual accounts filed late (26 days) Filed on 26 August 2025, deadline 31 July 2025 (7 months after the close on 31 December 2024, Companies Code art. 3:10). Source: NBB, 2025-00414646.
Turnover
≈ €5.0m
Estimated: probably between €3.4m and €8.2m
EBIT margin
Not included in this filing
Net result
-€11.0m▼ 90.2%
2023 · -€5.8m
Working capital
€1.1m▼ 73.5%
2023 · €4.1m
Trend over the years
2020 to 2024, 5 financial years 2018 to 2024, 7 financial years
The operating result stays negative: a loss of €16.6m in 2024 against €9.9m in 2023; the loss grows and 2024 has the lowest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result-€16.6m
2024
Net result-€11.0m
2024
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€3.8m
2024
Equity-€7.8m
2024
Debt€6.1m
2024
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€1.1m
2024
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)-292.9%
2024
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency-207.5%
2024
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.41
2024
Average staff in full-time equivalents (FTE).
Staff (FTE)22.4
2024
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line2018201920202021202220232024
Operating result-€3.7m--€3.9m▼ 4.7%-€6.4m▼ 66.3%-€7.9m▼ 23.4%-€8.1m▼ 2.6%-€9.9m▼ 22.1%-€16.6m▼ 67.3%
Net result-€2.4m--€2.7m▼ 13.1%-€3.6mbelow the sector's middle half▼ 35.2%-€5.3mbelow the sector's middle half▼ 46.7%-€6.0mbelow the sector's middle half▼ 12.8%-€5.8mbelow the sector's middle half▲ 3.1%-€11.0mbelow the sector's middle half▼ 90.2%
Equity€5.3m-€17.7m▲ 231%€11.4mabove the sector's middle half▼ 35.4%€20.8mabove the sector's middle half▲ 82.4%€9.0mabove the sector's middle half▼ 56.8%€3.2mwithin the sector's middle half▼ 64.3%-€7.8mbelow the sector's middle half
Total assets€7.5m-€21.1m▲ 182%€16.1mabove the sector's middle half▼ 23.7%€27.2mabove the sector's middle half▲ 68.5%€18.1mabove the sector's middle half▼ 33.4%€12.5mabove the sector's middle half▼ 31.0%€3.8mwithin the sector's middle half▼ 69.9%
Debt€2.1m-€3.4m▲ 60.8%€4.7m▲ 36.7%€5.9m▲ 26.4%€9.1m▲ 52.4%€9.3m▲ 2.2%€6.1m▼ 34.3%
Working capital€4.6m-€17.0m▲ 266%€11.3mabove the sector's middle half▼ 33.6%€21.9mabove the sector's middle half▲ 94.2%€11.0mabove the sector's middle half▼ 49.5%€4.1mabove the sector's middle half▼ 63.0%€1.1mwithin the sector's middle half▼ 73.5%
Solvency71.4%-83.7%▲ 12.3pp70.8%within the sector's middle half▼ 12.9pp76.7%within the sector's middle half▲ 5.9pp49.7%within the sector's middle half▼ 26.9pp25.7%within the sector's middle half▼ 24.0pp-207.5%below the sector's middle half▼ 233.2pp
Current ratio3.71-7.48▲ 3.764.27within the sector's middle half▼ 3.216.51above the sector's middle half▲ 2.242.97within the sector's middle half▼ 3.541.91within the sector's middle half▼ 1.061.41within the sector's middle half▼ 0.50
Return on assets (ROA)-31.6%--12.7%▲ 18.9pp-22.4%below the sector's middle half▼ 9.8pp-19.5%below the sector's middle half▲ 2.9pp-33.0%below the sector's middle half▼ 13.5pp-46.3%below the sector's middle half▼ 13.3pp-292.9%below the sector's middle half▼ 246.6pp
Staff (FTE)7.1-13▲ 83.1%15.1within the sector's middle half▲ 16.2%14.2within the sector's middle half▼ 6.0%15.3within the sector's middle half▲ 7.7%18.9within the sector's middle half▲ 23.5%22.4within the sector's middle half▲ 18.5%
above
within
below
the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
The turnover shown is an estimate from the gross margin.
Why a figure moved sharply
- 2024 Total assets -70% on 2023. Capital reduction of €3,000,000 (Official Gazette 15-04-2024).
- 2023 Equity -64% on 2022. Capital reduction of €3,237,782 (Official Gazette 04-07-2023).
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €3.8m
Fixed assets
€52,817 ▼ 98.6%
Current assets
€3.7m ▼ 56.8%
Equity and liabilities
Equity-€7.8m
Debt€6.1m
Equity is negative: debt (€6.1m) exceeds the balance-sheet total (€3.8m).
Key figures and ratios
EBITDA
-€6.6m▼
2023 · -€2.4m
Cash flow
-€1.0m▼
2023 · €1.7m
Interest coverage
-44.51▼
2023 · -38.84
Debt ≤ 1 year
€2.6m▼
2023 · €4.5m
Debt > 1 year
€3.5m▼
2023 · €4.7m
Income taxes
-€431,321▼
2023 · -€302,681
Staff costs
€1.6m▲
2023 · €1.5m
No debt to equity: equity is negative, so debt divided by equity means nothing.
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | €0.03m | €3.9m | ▲ 128× |
| Goods, raw materials, services and sundry goods60/61 | - | - | - | - | €6.6m | €8.1m | €7.2m | ▼ 11.4% |
| Remuneration, social security and pensions62 | - | - | - | €1.0m | €1.2m | €1.5m | €1.6m | ▲ 8.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €2.8m | €3.8m | €5.0m | €5.7m | €5.9m | €7.5m | €10.0m | ▲ 32.9% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €0.4m | €0.4m | -€0.2m | -€0.1m | ▲ 29.1% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | - | -€0.4m | -€0.02m | €5.5m | - |
| Other operating charges640/8 | - | - | - | €0.8m | €0.4m | €0.6m | €0.9m | ▲ 51.0% |
| Non-recurring operating charges66A | - | - | - | - | - | - | €1.6m | - |
| Gross operating margin9900 | -€0.2m | €1.0m | €0.07m | €0.08m | -€0.6m | -€0.5m | €2.9m | - |
| Operating profit (loss)9901 | -€3.7m | -€3.9m | -€6.4m | -€7.9m | -€8.1m | -€9.9m | -€16.6m | ▼ 67.3% |
| Financial income75/76B | - | - | - | €2.4m | €2.0m | €3.9m | €6.2m | ▲ 60.0% |
| Recurring financial income75 | €1.2m | €1.2m | €2.7m | €2.4m | €2.0m | €3.9m | €6.2m | ▲ 60.0% |
| Non-recurring financial income76B | - | - | - | €0.002m | €0.001m | - | - | - |
| Financial charges65/66B | - | - | - | €0.02m | €0.06m | €0.06m | €1.1m | ▲ 17× |
| Recurring financial charges65 | €0.01m | €0.07m | €0.04m | €0.02m | €0.06m | €0.06m | €0.1m | ▲ 141% |
| Non-recurring financial charges66B | - | - | - | - | - | - | €0.9m | - |
| Profit (loss) for the period before taxes9903 | -€2.5m | -€2.7m | -€3.8m | -€5.5m | -€6.2m | -€6.1m | -€11.4m | ▼ 87.9% |
| Income taxes67/77 | -€0.1m | -€0.03m | -€0.2m | -€0.2m | -€0.2m | -€0.3m | -€0.4m | ▼ 42.5% |
| Profit (loss) for the period9904 | -€2.4m | -€2.7m | -€3.6m | -€5.3m | -€6.0m | -€5.8m | -€11.0m | ▼ 90.2% |
| Profit (loss) for the period to be appropriated9905 | -€2.4m | -€2.7m | -€3.6m | -€5.3m | -€6.0m | -€5.8m | -€11.0m | ▼ 90.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €7.5m | €21.1m | €16.1m | €27.2m | €18.1m | €12.5m | €3.8m | ▼ 69.9% |
| Fixed assets21/28 | €1.1m | €1.5m | €1.4m | €1.3m | €1.4m | €3.9m | €0.05m | ▼ 98.6% |
| Intangible fixed assets21 | €0.01m | €0.05m | €0.03m | €0.02m | €0.05m | €0.1m | €0 | ▼ 100% |
| Tangible fixed assets22/27 | €0.2m | €0.6m | €0.4m | €0.4m | €0.5m | €2.9m | €0.05m | ▼ 98.2% |
| Land and buildings22 | - | - | - | - | - | €0 | - | - |
| Plant, machinery and equipment23 | - | - | - | €0.1m | €0.09m | €0.7m | €0.04m | ▼ 94.4% |
| Furniture and vehicles24 | - | - | - | €0.03m | €0.02m | €0.3m | €0.01m | ▼ 94.6% |
| Leasing and similar rights25 | - | - | - | €0.2m | €0.08m | €0.8m | €0 | ▼ 100% |
| Other tangible fixed assets26 | - | - | - | €0.02m | €0.03m | €0.6m | €0 | ▼ 100% |
| Assets under construction and advance payments27 | - | - | - | - | €0.3m | €0.5m | €0 | ▼ 100% |
| Financial fixed assets28 | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0 | ▼ 100% |
| Current assets29/58 | €6.3m | €19.6m | €14.7m | €25.9m | €16.6m | €8.6m | €3.7m | ▼ 56.8% |
| Amounts receivable after more than one year29 | - | - | - | €3.4m | €0.6m | €1.2m | €0 | ▼ 100% |
| Other amounts receivable291 | - | - | - | €3.4m | €0.6m | €1.2m | €0 | ▼ 100% |
| Amounts receivable within one year40/41 | €4.9m | €6.4m | €3.3m | €11.5m | €4.9m | €2.8m | €0.7m | ▼ 73.0% |
| Trade receivables40 | - | - | - | €5.8m | €1.5m | €0.4m | €0.1m | ▼ 65.4% |
| Other amounts receivable41 | - | - | - | €5.7m | €3.3m | €2.4m | €0.6m | ▼ 74.3% |
| Current investments50/53 | - | - | €6.0m | €0 | - | €1.0m | - | - |
| Cash at bank and in hand54/58 | €1.4m | €13.2m | €2.5m | €10.9m | €11.1m | €2.5m | €2.8m | ▲ 12.6% |
| Deferred charges and accrued income490/1 | - | - | - | €0.03m | €0.1m | €1.2m | €0.2m | ▼ 84.5% |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €7.5m | €21.1m | €16.1m | €27.2m | €18.1m | €12.5m | €3.8m | ▼ 69.9% |
| Equity10/15 | €5.3m | €17.7m | €11.4m | €20.8m | €9.0m | €3.2m | -€7.8m | - |
| Contributions10/11 | €3.7m | €6.2m | €6.2m | €31.4m | €31.4m | €3.2m | €1.2m | ▼ 64.0% |
| Capital10 | - | - | - | €7.2m | €7.2m | €1.0m | €1.0m | = |
| Issued capital100 | - | - | - | €7.2m | €7.2m | €1.0m | €1.0m | = |
| Contributions outside capital11 | - | - | - | €24.1m | €24.1m | €2.2m | €0.2m | ▼ 93.0% |
| Share premium1100/10 | - | - | - | €24.1m | €24.1m | €2.2m | €0.2m | ▼ 93.0% |
| Profit (loss) carried forward14 | -€4.8m | -€7.5m | -€11.1m | -€16.4m | -€22.4m | - | -€9.0m | - |
| Investment grants15 | - | - | - | €5.8m | - | - | - | - |
| Provisions and deferred taxes16 | - | - | - | €0.4m | €0.03m | €0.01m | €5.5m | ▲ 522× |
| Provisions for liabilities and charges160/5 | - | - | - | €0.4m | €0.03m | €0.01m | €5.5m | ▲ 522× |
| Other liabilities and charges164/5 | - | - | - | €0.4m | €0.03m | €0.01m | €5.5m | ▲ 522× |
| Amounts payable17/49 | €2.1m | €3.4m | €4.7m | €5.9m | €9.1m | €9.3m | €6.1m | ▼ 34.3% |
| Amounts payable after more than one year17 | €0.4m | €0.8m | €1.3m | €2.0m | €3.5m | €4.7m | €3.5m | ▼ 26.1% |
| Financial debts170/4 | - | - | - | €0.08m | €0.02m | €1.2m | €1.5m | ▲ 30.9% |
| Other amounts payable178/9 | - | - | - | €1.9m | €3.5m | €3.5m | €2.0m | ▼ 44.7% |
| Amounts payable within one year42/48 | €1.7m | €2.6m | €3.4m | €4.0m | €5.6m | €4.5m | €2.6m | ▼ 41.6% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.09m | €0.06m | €0.4m | €0.7m | ▲ 89.9% |
| Trade debts44 | €1.6m | €2.5m | €3.3m | €3.7m | €3.2m | €3.8m | €1.6m | ▼ 56.4% |
| Suppliers440/4 | - | - | - | €3.7m | €3.2m | €3.8m | €1.6m | ▼ 56.4% |
| Taxes, remuneration and social security45 | - | - | - | €0.2m | €0.2m | €0.2m | €0.2m | ▼ 33.4% |
| Taxes450/3 | - | - | - | - | - | €0.005m | €0.007m | ▲ 56.5% |
| Remuneration and social security454/9 | - | - | - | €0.2m | €0.2m | €0.2m | €0.2m | ▼ 35.1% |
| Other amounts payable47/48 | - | - | - | €0.009m | €2.2m | €0.1m | €0.2m | ▲ 16.2% |
| Accrued charges and deferred income492/3 | - | - | - | €0.001m | - | €0.09m | €0 | ▼ 100% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€2.4m | -€2.7m | -€3.6m | -€5.3m | -€6.0m | -€5.8m | -€11.0m | ▼ 90.2% |
| + Depreciation and write-downs630 | €2.8m | €3.8m | €5.0m | €5.7m | €5.9m | €7.5m | €10.0m | ▲ 32.9% |
| Operating cash flow (approximation) | €0.4m | €1.1m | €1.4m | €0.4m | -€0.06m | €1.7m | -€1.0m | - |
| Investment in fixed assets (approximation) | - | -€4.2m | -€4.9m | -€5.6m | -€6.1m | -€10.0m | -€6.1m | ▲ 38.5% |
| Change in cash | - | €11.8m | -€10.8m | €8.4m | €0.2m | -€8.6m | €0.3m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (9)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | full format | 26-08-2025 | 2025-00414646 |
| 31-12-2023 | full format | 28-06-2024 | 2024-00215594 |
| 31-12-2022 | full format | 18-06-2023 | 2023-00153878 |
| 31-12-2021 | full format | 07-06-2022 | 2022-20056128 |
| 31-12-2020 | full format | 23-06-2021 | 2021-24200138 |
| 31-12-2019 | full format | 24-06-2020 | 2020-20500313 |
| 31-12-2018 | full format | 18-06-2019 | 2019-21400372 |
| 31-12-2017 | full format | 02-07-2018 | 2018-27400024 |
| 31-12-2016 | full format | 23-08-2017 | 2017-49300156 |
Similar companies · same sector, comparable size
BIOMEDICAL SYSTEMS
BE 0421.984.741
Leuven · FTE 22.3
Microbial Resource Management Health
BE 0742.910.132
Gent · FTE 22.8
ONCORADIOMICS
BE 0662.719.440
Liège · FTE 23.4
NewMilkLab
BE 0896.615.540
Gent · FTE 21.4
Precirix
BE 0564.736.473
Jette · FTE 21.1
Of the 760 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 483. 147 are within a factor 10 of this headcount. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.